Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Only about 3% of cancer drugs make from trials

http://www.ipharminc.com/press-release/2016/11/16/cellceutix-reports-spleen-lesion-disappears-in-patient-with-metastatic-stage-4-ovarian-cancer-in-clinical-trial-of-anti-cancer-drug-kevetrin

Cellceutix Reports Spleen Lesion ‘Disappears’ in Patient with Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin

is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company’s Phase 1 clinical trial of anti-cancer drug candidate Kevetrin™

Dapto patent cliff was a know thing

Wish someone told fearless leader that:

http://www.ipharminc.com/press-release/2016/11/16/cellceutix-provides-corporate-update?rq=cubicin

In our completed 215-patient Phase 2b trial of Brilacidin ABSSSI, two different single dose treatments of Brilacidin, as well as a three-day regimen, were all shown to be comparably effective as the FDA-approved 7-day dosing regimen of the blockbuster antibiotic daptomycin. In 2014, daptomycin was marketed under that brand name Cubicin by Cubist Pharmaceuticals and generated $1.046 billion in sales. In December 2014, Merck & Co. agreed to acquire Cubist Pharmaceuticals for approximately $9.5 billion, including debt.

So was Leo dumb or pumping? Personally I give him the benefit of the doubt. He was an accountant in over his head.

Go IPIX!